Peripheral Treg Levels and Transforming Growth Factor-β (TGFβ) in Patients with Psoriatic Arthritis: A Systematic Review Meta-Analysis

Su, Q. Y.; Zhang, Sheng‐Xiao; Liu, Yang; Li, Xiaofeng; Zhang, Jiaqi; Zhang, Yan; Liu, Junqi; Shi, Lei

doi:10.1007/s12325-022-02337-5

Cited by 3 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recently published meta-analysis, the authors showed decreased levels of several subtypes of T regs in this group of patients, in particular CD4+ CD25+FoxP3+ T regs and CD4+CD25highCD127low T regs . Subjects with PsA also had lower levels of transforming growth factor beta (TGFβ) [12].…”

Section: Discussionmentioning

confidence: 99%

The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

Adamczyk,

Bartosińska,

Raczkiewicz

et al. 2023

JCM

View full text Add to dashboard Cite

CD (cluster of differentiation) 69 and CD25 are considered early and late markers of the activation of lymphocytes, respectively. CD25 is a part of the IL-2 receptor and is present on the surface of immune and non-immune cells, with high amounts on activated lymphocytes and regulatory T cells. CD69 is expressed on various types of white blood cells, including newly activated lymphocytes, lymphocytes infiltrating tissues isolated from subjects with chronic auto-inflammatory diseases, several subtypes of memory T cells and regulatory T cells. Primarily, CD69 was considered to be an early marker of the activation of lymphocytes, but, right now, data derived from in vitro and in vivo studies have revealed the immunomodulatory role of this surface antigen. In 84 patients with psoriasis, of whom 28 were treated with different biologic drugs, as well as in 29 healthy control subjects, the expression of CD25 and CD69 on different subtypes of peripheral blood mononuclear cells (PBMCs) was studied with the use of flow cytometry. Significantly higher levels of CD3/CD69-, CD8/CD69- and CD19/CD69-positive PBMCs as well as within CD3+ cells were present in subjects suffering from psoriasis when compared to healthy controls. In patients with psoriasis who were treated with biologic drugs, the levels of CD3/CD69-, CD4/CD69- and CD19/CD69-positive PBMCs, and CD3/CD69 within CD3+ cells, CD4/CD69 within CD4+ cells, CD4/CD25 within CD4+ cells and CD19/CD69 within CD19+ cells were significantly higher than before therapy. Our results support a role for activation markers, especially CD69, in psoriasis. Further research is warranted to fully clarify their significance in this common dermatosis, especially during biologic treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

Adamczyk,

Bartosińska,

Raczkiewicz

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…[8,[10][11][12][13]. Regulatory T cells (Tregs), a specific subset of T cells, are functionally changed in different autoimmune diseases [14][15][16][17][18][19][20], including MS [21][22][23][24][25][26]. Treg cells are distinguished as a CD4+ T cell subset that express the interleukin-2 receptor alpha chain CD25 and the pivotal transcription factor Forkhead box protein P3 (FOXP3).…”

Section: Introductionmentioning

confidence: 99%

Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells

Ipavec,

Rogić Vidaković,

Markotić

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The objective of this study was to investigate regulatory T cells (Tregs) and monocytes; specifically, the expression of CTLA-4 (CD152) and FOXP3+ in CD4+CD25+ Tregs and the expression of CD40+ and CD192+ monocyte subpopulations in subjects with primary progressive multiple sclerosis (PPMS). Immunological analysis was conducted on peripheral blood samples collected from the 28 PPMS subjects (15 treated with ocrelizumab and 13 untreated PPMS subjects) and 10 healthy control subjects (HCs). The blood samples were incubated with antihuman CD14, CD16, CD40, and CD192 antibodies for monocytes and antihuman CD4, CD25, FOXP3, and CTLA-4 antibodies for lymphocytes. The study results showed that in comparison to HCs both ocrelizumab treated (N = 15) and untreated (N = 13) PPMS subjects had significantly increased percentages of CTLA-4+ and FOXP3+ in CD4+CD25+ Tregs. Further, ocrelizumab treated PPMS subjects, compared to the untreated ones, had significantly decreased percentages of CD192+ and CD40+ nonclassical monocytes. Increased percentages of CTLA-4+ and FOXP3+ in CD4+CD25+ Tregs in both ocrelizumab treated and untreated PPMS subjects indicates the suppressive (inhibitory) role of Tregs in abnormal immune responses in PPMS subjects. Decreased percentages of CD40+, CD192+, and CD14+CD16++ monocytes for treated compared to untreated PPMS subjects suggests a possible role for ocrelizumab in dampening CNS inflammation.

show abstract

Peripheral Th17/Treg imbalance in Chinese patients with untreated antisynthetase syndrome associated interstitial lung disease

Wang,

Li,

et al. 2024

International Immunopharmacology

View full text Add to dashboard Cite

Peripheral Treg Levels and Transforming Growth Factor-β (TGFβ) in Patients with Psoriatic Arthritis: A Systematic Review Meta-Analysis

Cited by 3 publications

References 38 publications

The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells

Peripheral Th17/Treg imbalance in Chinese patients with untreated antisynthetase syndrome associated interstitial lung disease

Contact Info

Product

Resources

About